UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
Categories News Press Releases Archives 2026 August July June May April March February 2025 December November October September August July June May April March February January 2024 December November October September August July June May April March February January 2023 December November October September August July June April February January Nov 03 U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) Read More
